Home > Dermatology > Rapid pustule and skin clearance with IL-36 receptor inhibitor spesolimab

Rapid pustule and skin clearance with IL-36 receptor inhibitor spesolimab

Presented By
Prof. Hervé Bachelez, Hôpital Saint-Louis, France
Conference
WPPAC 2021
Trial
Phase 2, Effisayil 1
The first randomised, placebo-controlled trial in patients with generalised pustular psoriasis (GPP) demonstrated that IL-36 receptor inhibition with spesolimab resulted in rapid improvements in signs and symptoms of flares versus placebo, with sustained effects and a favourable benefit-risk profile [1]. GPP is a rare, potentially life-threatening, multisystemic autoinflammatory disease characterised by widespread recurrent flares of sterile pustules on the skin. Dysregulation of the IL-36 pathway appears to be central in its pathogenesis [2]. Currently, no therapies have been approved for flares of GPP in the USA or Europe. In a previous phase 1 study (NCT02978690), a single intravenous dose of spesolimab resulted in rapid pustule clearance in patients with GPP [3]. The subsequent phase 2 Effisayil 1 study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on